Single-agent activity of gemcitabine in advanced non-small cell lung cancer.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Seminars in Oncology

• Publication date

  1996-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 8893880
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I studies with the novel nucleoside analog gemcitabine.

  1996cited by this paper
• Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.

  1996cited by this paper
• Gemcitabine: preclinical pharmacology and mechanisms of action.

  1996cited by this paper
• Gemcitabine safety overview.

  1996cited by this paper
• Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms

  1995cited by this paper
• Chemotherapy for advanced non-small-cell lung cancer.

  1994cited by this paper
• Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.

  1994cited by this paper
• Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

  1994cited by this paper
• Treatment of non-small cell lung cancer: new cytostatic agents.

  1993cited by this paper
• New chemotherapeutic agents in non-small-cell lung cancer.

  1993cited by this paper
• Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.

  1988cited by this paper

• DSG2 attenuates gemcitabine efficacy through PTX3 in lung adenocarcinoma.

  2025cites this paper
• Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals.

  2008cites this paper
• Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study

  2008cites this paper
• Prise en charge des cancers solides et des hémopathies malignes du sujet âgé : l’oncogériatrie une discipline en devenir

  2005cites this paper
• Original Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study

  2005cites this paper
• [Treatment of cancer and hematological malignancy in elderly people: oncogeriatrics as a discipline for the future (Part I): geriatric evaluation and management of solid tumors].

  2005cites this paper
• First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule.

  2005cites this paper
• Efficacy of gemcitabine--cisplatin treatment in stage IIIA ("bulky"N2), IIIB and IV non-small cell lung cancer.

  2005cites this paper
• Medizinische Evidenz und Versorgungsrealität in der Therapie von NSCLC und Pankreaskarzinom - Erkenntnisse aus einer Anwendungsbeobachtung

  2004cites this paper
• Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

  2004cites this paper
• Treatment of locally advanced and metastatic non-small cell lung cancer in the elderly.

  2004cites this paper
• Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer.

  2003cites this paper
• [New drugs in bronchial cancer].

  2002cites this paper
• Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975.

  2002cites this paper
• Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.

  2001cites this paper
• Combined use of gemcitabine and radiation in mice.

  2001cites this paper
• Triplet combination chemotherapy and targeted therapy regimens.

  2001cites this paper
• Gemcitabine as single agent therapy in advanced non small cell lung cancer and quality of life in the elderly.

  2001cites this paper
• Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).

  2000cites this paper
• Gemcitabine in the treatment of bladder cancer

  2000cites this paper
• Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer.

  2000cites this paper
• NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).

  2000cites this paper
• Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study.

  1999cites this paper
• Activity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas.

  1999cites this paper
• Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer.

  1999cites this paper
• Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer

  1999cites this paper
• Should all Stage IV Non-Small Cell Lung Cancer Be Treated Palliatively?

  1999cites this paper
• Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma.

  1999cites this paper
• New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.

  1998cites this paper
• Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.

  1998cites this paper
• Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.

  1998cites this paper
• Gemcitabine: Future Prospects of Single-Agent and Combination Studies.

  1997cites this paper
• Phase I studies of gemcitabine combined with carboplatin or paclitaxel.

  1997cites this paper